ESC Premium Access

Iron deficiency and athletic performance

Congress Presentation

About the speaker

Doctor Emese Csulak

Semmelweis University Heart and Vascular Center, Budapest (Hungary)
0 follower

33 more presentations in this session

Hybrid cardiac telerehabilitation program as a potential strengthening factor in the quality of life in patients with coronary heart disease: a retrospective single-centre analysis

Speaker: Doctor M. Cabral (Leiria, PT)

Thumbnail

The effects of dual task training on the neurophysiological parameters in cardiac surgery patients: a pilot study

Speaker: Doctor I. Tarasova (Kemerovo, RU)

Thumbnail

Differences in mitral and tricuspid annular geometry in elite athletes with versus without functional mitral regurgitation: a 3D echocardiographic study

Speaker: Doctor A. Fabian (Budapest, HU)

Thumbnail

Influence of resistance exercise on cardiac remodeling and soleus muscle of infarcted rats

Speaker: Professor M. Okoshi (Botucatu, BR)

Thumbnail

Effects of physical prehabilitation on markers of endothelial function in patients undergoing elective coronary artery bypass grafting

Speaker: Doctor Y. Argunova (Kemerovo, RU)

Thumbnail

Access the full session

Rehabilitation and Sports Cardiology ePosters

Speakers: Doctor E. Csulak, Doctor M. Cabral, Doctor I. Tarasova, Doctor A. Fabian, Professor M. Okoshi...
Thumbnail

About the event

Image

ESC Congress 2021 - The Digital Experience

27 August - 30 August 2021

Sessions Presentations

Related content

ESC Premium Access

Right ventricle morphological and functional phenotypes in heart failure with reduced ejection fraction: from pathophysiology to prognostic significance

27 August 2021

ESC Premium Access

Effect of empagliflozin in hfref patients treated with angiotensin receptor neprilysin inhibitor an analysis of EMPIRE HF

27 August 2021

ESC Premium Access

Case report on a transthyretin-related amyloidosis caused by Leu32Val mutation and its interdisciplinary challenge.

27 August 2021

ESC 365 is supported by

logo Novo Nordisk